Excelsior Reach Microcatheter
Stryker Neurovascular · Decision date Oct 9, 2026
What did the FDA decide?
Stryker Neurovascular received a substantially equivalent (SESE) decision for the Excelsior Reach Microcatheter under 510(k) K261649, dated October 9, 2026. This is a clearance, not a PMA approval. The device is a single-lumen, single-use, sterile percutaneous catheter classified under 21 CFR 870.1250 (Class II), with primary product code QJP and subsequent code DQY; the FDA database lists the regulation medical specialty as Cardiovascular and the review panel as Neurology.
The submission describes a catheter offered in 155 cm and 165 cm effective lengths and straight or pre-shaped tips, with two distal radiopaque markers, a Luer hub, and a hydrophilic coating, supplied with a peel-away introducer sheath and steam-shaping accessories. The summary names the Excelsior SL-10 Pre-Shaped Microcatheter (K042568) as predicate and the Headway Duo Microcatheter (K120917) as reference. Bench testing listed in the summary is reported as passing; the record does not include clinical outcome data, and the labeled six-month shelf life is stated without supporting results detail.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 9, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K261649
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Stryker Neurovascular
- Product code
- QJP
- Decision code
- SESE
- Decision date
- Oct 9, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Catheter, Percutaneous, Neurovasculature.
- Applicant
- Stryker Neurovascular
- Product code
- QJP
- FDA device class
- 2
FDA decision timeline
K261649 received
Application receipt date recorded by FDA.
K261649 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code QJP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
NeuroSheathK261449 | Perfuze, Ltd. | 510(k) clearance | Nov 5, 2026 | FDA |
APRO 88 CatheterK261938 | Alembic, LLC | 510(k) clearance | Oct 6, 2026 | FDA |
OAB Delivery CatheterK253422 | Cognition Medical Corp. | 510(k) clearance | Oct 2, 2026 | FDA |
| Route 92 Medical, Inc. | 510(k) clearance | Sep 16, 2026 | FDA | |
70 NeuGlide CatheterK262277 | Piraeus Medical, Inc. | 510(k) clearance | Sep 4, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Stryker Neurovascular
- Headquarters
- Not reported
- Brand website
- stryker.com
- FDA applicant address
- Fremont, CA
Sources and methodology
- Original FDA record: K261649
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

